机译:VEGFR-3及其配体VEGF-C与乳腺癌血管生成有关。
From the Molecular/Cancer Biology Laboratory and Department of Pathology,GBF, Braunschweig, Germany;
Haartman Institute, University of Helsinki, the Department of Oncology,GBF, Braunschweig, Germany;
From the Molecular/Cancer Biology Laboratory and Department of Pathology,GBF, Braunschweig, Germany;
From the Molecular/Cancer Biology Laboratory and Department of Pathology,GBF, Braunschweig, Germany;
Haartman Institute, University of Helsinki, the Department of Oncology,GBF, Braunschweig, Germany;
Helsinki University Central Hospital, Helsinki, the Collagen Research Unit, Biocenter, Department of Medical Biochemistry,GBF, Braunschweig, Germany;
Helsinki University Central Hospital, Helsinki, the Collagen Research Unit, Biocenter, Department of Medical Biochemistry,GBF, Braunschweig, Germany;
University Hospital, Nijmegen, The Netherlands, and the Department of Gene Expression,GBF, Braunschweig, Germany;
University of Oulu, Oulu, Finland, the Department of Pathology,GBF, Braunschweig, Germany;
From the Molecular/Cancer Biology Laboratory and Department of Pathology,GBF, Braunschweig, Germany;
机译:乳腺癌不同分子类型中的淋巴微血管密度,VEGF-C和VEGFR-3表达。
机译:VEGF-C与VEGFR-3结合可促进具有广泛导管内成分的乳腺癌的淋巴结转移,但不会刺激其周围的淋巴管生长
机译:雷帕霉素通过下调VEGF-A / VEGFR-2和VEGF-C / VEGFR-3的表达抑制黑色素瘤的血管生成和淋巴管生成
机译:噬菌体展示作为乳腺癌新疗法的开发的工具:靶向人δ样的配体1 Notch1配体
机译:癌症纳米技术:基于配体的纳米结构,可增强乳腺癌中抗癌药物的抗肿瘤活性。
机译:VEGFR-3及其配体VEGF-C与乳腺癌血管生成有关。
机译:VEGFR-3及其配体VEGF-C与乳腺癌血管生成有关。